Complement Inhibitors Market to Hit $35.1 Billion by 2036 as New Approvals Drive 10.7% CAGR
Updated
Updated · futuremarketinsights.com · Aug 8
Complement Inhibitors Market to Hit $35.1 Billion by 2036 as New Approvals Drive 10.7% CAGR
1 articles · Updated · futuremarketinsights.com · Aug 8
Summary
$35.1 billion is the projected size of the complement inhibitors market by 2036, up from $12.7 billion in 2026, implying a 10.7% annual growth rate.
New approvals are widening use beyond established C5 blockade into C3, factor B and lectin-pathway drugs, extending treatment across kidney, blood, neuromuscular and retinal disorders.
C5 inhibitors are still expected to lead with 46% of 2026 demand, while PNH remains the biggest application at 34%, reflecting the most mature specialist treatment pathway.
Hospitals are forecast to capture 41% of end-user demand and intravenous drugs 52% of route share in 2026 because initiation, vaccination checks and infection-risk monitoring remain concentrated in specialist centers.
The outlook still faces access constraints: reimbursement reviews and serious infection warnings can slow onboarding even as oral and subcutaneous options reduce repeat infusion visits.